#United Kingdom #Oxford #HFpEF #Ultromics #EchoGo

Ultromics Enhances EchoGo® Heart Failure with AI-Powered Probability Scoring

Ultromics, a leader in artificial intelligence-related innovations in cardiology, has made a significant stride forward with its latest enhancement to the EchoGo® Heart Failure platform. This new development introduces an AI-driven probability scoring system specifically designed to address the common yet often misdiagnosed condition known as heart failure with preserved ejection fraction (HFpEF). By applying deep learning technologies, Ultromics aims to substantially improve detection rates and clinical decision-making for this complex heart condition.

The Breakthrough of AI in HFpEF Diagnosis

The EchoGo® Heart Failure platform is already recognized as the first and only artificial intelligence solution that can identify HFpEF from standard echocardiograms. The introduction of the probability scoring system adds a layer of precision to this capability, providing clinicians with a continuous score representing the likelihood of HFpEF. This nuanced approach minimizes uncertainty associated with diagnosing such an intricate condition, ultimately enhancing clinicians’ decision-making confidence.

According to Dr. Ross Upton, CEO and founder of Ultromics, “The probability scoring feature is a pivotal advancement that will transform how heart failure is detected and how patient risks are stratified.” This unique feature enables healthcare providers to more accurately gauge a patient's likelihood of having HFpEF, paving the way for more informed clinical decisions.

Clinical Validation and Real-World Impact

The effectiveness of this new feature has been rigorously tested in a study conducted at Beth Israel Deaconess Medical Center, a teaching hospital affiliated with Harvard Medical School. This clinical validation involved complex, real-world cases of patients who presented various overlapping health challenges, which typically complicate diagnosis. The results indicated that the AI-powered scoring system significantly enhances the identification of HFpEF, distinctly improving patient outcomes and diagnostic accuracy.

Notably, patients categorized as high-risk by the EchoGo® system demonstrated a twofold increase in hospital admissions and a concerning rise in mortality rates. This underscores the importance of using AI tech for proactive patient management within clinical settings.

In direct comparison with traditional diagnostic methods, the EchoGo® Heart Failure platform not only achieved higher sensitivity in identifying HFpEF cases but also showed a marked improvement in differentiating between HFpEF and patients without a confirmed diagnosis. Evidence revealed that using EchoGo® resulted in more than an 80% definitiveness rate in outcomes, significantly reducing the frequency of inconclusive diagnoses prevalent in conventional models.

Features That Set EchoGo® Apart

In tackling the daunting diagnosis of HFpEF, the EchoGo® Heart Failure system merges various clinical and echocardiographic parameters to form a continuous scoring model. This innovative approach facilitates a more detailed understanding of a patient’s risk level regarding HFpEF, ultimately reducing the complexity and ambiguity often involved in diagnosing this disease.

Some pivotal features of the upgraded EchoGo® Heart Failure platform include:

• - Probability-Based Scoring: This AI evaluates echocardiogram sequences to provide risk scores that reflect HFpEF patterns.
• - Uncertainty Estimates: Each score comes with an uncertainty rating, flagging uncertain predictions for further assessment, thereby minimizing false diagnoses.
• - Comparative Analysis Visualization: Clinicians can juxtapose patient results against a comprehensive population data set of both HFpEF and non-HFpEF cases, facilitating objective assessments.

Backed by FDA Device Breakthrough clearance, this cutting-edge feature is now active and available for healthcare professionals. For those interested in a demonstration or more information, Ultromics encourages reaching out via their official website.

About Ultromics

Founded at the University of Oxford, Ultromics is at the forefront of pioneering health technology aimed at revolutionizing cardiac care through AI capabilities. Heart disease continues to be the leading cause of death globally, necessitating urgent solutions. The company collaborates with prominent organizations such as Pfizer and Mayo Clinic to create innovative diagnostic tools designed to enhance heart disease detection worldwide, thereby showcasing a commitment to setting new standards for AI applications in cardiovascular imaging.